Of more than 50
therapeutic vaccine trials so far, this is the first one that has bolstered the immune system in a «meaningful» way, says Steven Deeks, an HIV / AIDS clinician and researcher at the University of California, San Francisco, who is «cautiously optimistic» that the data will inspire others to study the approach.
Not exact matches
SAN FRANCISCO — A
therapeutic vaccine against severe rotaviral diarrhea, which kills nearly 900,000 infants worldwide each year, has succeeded in clinical
trials.
A 2010 survey by the market analysis firm BCC Research identified 113
therapeutic vaccines in development, many already in human
trials.
The Johns Hopkins scientists who conducted the
trial said the finding is significant because measuring immune system responses directly in the lesions may be a more accurate way to evaluate so - called «
therapeutic»
vaccines than by the conventional means of blood analysis.
A new
therapeutic vaccine, GTL001, developed by Genticel to clear HPV strains 16 and 18 — the types most likely to cause cancer — is being evaluated for safety in a Phase I clinical
trial at the University of Louisville.
The
trial was part of the Cancer
Vaccine Collaborative, a joint program between the Cancer Research Institute and the Ludwig Institute for Cancer Research to develop
therapeutic cancer
vaccines.
MHRP's international research program has six clinical research sites in the U.S., Africa and Asia, where it conducts HIV cohort studies, HIV
vaccine trials and
therapeutic studies.
In addition to preventive
vaccines, such as Gardasil and Cervarix, laboratory research and several human clinical
trials are focused on the development of
therapeutic HPV
vaccines.
Most recently, CRI has launched a new «venture philanthropy» program called the Cancer
Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next - generation
therapeutic cancer
vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical
trials.
«We have made many prophylactic and
therapeutic vaccines for use in human clinical
trials.»
«Based on the clinical evidence we've gathered over the past decade in our cancer
vaccine trials,» Old said, «and in light of data from a variety of
trials by others within the field, we believe
therapeutic cancer
vaccines will increasingly emerge as one of the safest and most powerful ways to combat a variety of cancers.»